FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584184235> ?p ?o ?g. }

• W2584184235 endingPage "1385" @default.
• W2584184235 startingPage "1373" @default.
• W2584184235 abstract "Objectives: Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with cefepime. Methods: CLSI agar dilution MICs were determined with cefepime/zidebactam in a chequerboard format. Bactericidal activity was also measured. Results: Zidebactam MICs were ≤2 mg/L (mostly 0.12–0.5 mg/L) for most Escherichia coli, Klebsiella, Citrobacter and Enterobacter spp., but were >32 mg/L for Proteeae, most Serratia and a few E. coli, Klebsiella and Enterobacter/Citrobacter. The antibacterial activity of zidebactam dominated chequerboard studies for Enterobacteriaceae, but potentiation of cefepime was apparent for zidebactam-resistant isolates with class A and C enzymes, illustrating β-lactamase inhibition. Overall, cefepime/zidebactam inhibited almost all Enterobacteriaceae with AmpC, ESBL, K1, KPC and OXA-48-like β-lactamases at 1 + 1 mg/L and also 29 of 35 isolates with metallo-carbapenemases, including several resistant to zidebactam alone. Zidebactam MICs for 36 of 50 Pseudomonas aeruginosa were 4–16 mg/L, and the majority of AmpC, metallo-β-lactamase-producing and cystic fibrosis isolates were susceptible to cefepime/zidebactam at 8 + 8 mg/L. Zidebactam MICs for Acinetobacter baumannii and Stenotrophomonas maltophilia were >32 mg/L; potentiation of cefepime was frequent for S. maltophilia, but minimal for A. baumannii. Kill curve results largely supported MICs. Conclusions: Zidebactam represents a second triple-action DBO following RG6080, with lower MICs for Enterobacteriaceae and P. aeruginosa. Clinical evaluation of cefepime/zidebactam must critically evaluate the reliance that can be placed on this direct antibacterial activity and on the enhancer effect as well as β-lactamase inhibition." @default.
• W2584184235 created "2017-02-10" @default.
• W2584184235 creator A5000013450 @default.
• W2584184235 creator A5035038696 @default.
• W2584184235 creator A5047369494 @default.
• W2584184235 creator A5060608792 @default.
• W2584184235 creator A5072423246 @default.
• W2584184235 date "2017-02-03" @default.
• W2584184235 modified "2023-09-30" @default.
• W2584184235 title "In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria" @default.
• W2584184235 cites W1893936760 @default.
• W2584184235 cites W1955380492 @default.
• W2584184235 cites W1976823789 @default.
• W2584184235 cites W2018229558 @default.
• W2584184235 cites W2019705526 @default.
• W2584184235 cites W2099140790 @default.
• W2584184235 cites W2101004558 @default.
• W2584184235 cites W2106565661 @default.
• W2584184235 cites W2109730521 @default.
• W2584184235 cites W2115118328 @default.
• W2584184235 cites W2125082290 @default.
• W2584184235 cites W2138910938 @default.
• W2584184235 cites W2157925105 @default.
• W2584184235 cites W2271108479 @default.
• W2584184235 cites W2396200281 @default.
• W2584184235 cites W2505961383 @default.
• W2584184235 doi "https://doi.org/10.1093/jac/dkw593" @default.
• W2584184235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28158732" @default.
• W2584184235 hasPublicationYear "2017" @default.
• W2584184235 type Work @default.
• W2584184235 sameAs 2584184235 @default.
• W2584184235 citedByCount "107" @default.
• W2584184235 countsByYear W25841842352017 @default.
• W2584184235 countsByYear W25841842352018 @default.
• W2584184235 countsByYear W25841842352019 @default.
• W2584184235 countsByYear W25841842352020 @default.
• W2584184235 countsByYear W25841842352021 @default.
• W2584184235 countsByYear W25841842352022 @default.
• W2584184235 countsByYear W25841842352023 @default.
• W2584184235 crossrefType "journal-article" @default.
• W2584184235 hasAuthorship W2584184235A5000013450 @default.
• W2584184235 hasAuthorship W2584184235A5035038696 @default.
• W2584184235 hasAuthorship W2584184235A5047369494 @default.
• W2584184235 hasAuthorship W2584184235A5060608792 @default.
• W2584184235 hasAuthorship W2584184235A5072423246 @default.
• W2584184235 hasBestOaLocation W25841842351 @default.
• W2584184235 hasConcept C104317684 @default.
• W2584184235 hasConcept C176947019 @default.
• W2584184235 hasConcept C2775945818 @default.
• W2584184235 hasConcept C2776315533 @default.
• W2584184235 hasConcept C2776352461 @default.
• W2584184235 hasConcept C2777050379 @default.
• W2584184235 hasConcept C2777058267 @default.
• W2584184235 hasConcept C2777637488 @default.
• W2584184235 hasConcept C2778523567 @default.
• W2584184235 hasConcept C2778910516 @default.
• W2584184235 hasConcept C2778983983 @default.
• W2584184235 hasConcept C2779631663 @default.
• W2584184235 hasConcept C2780493024 @default.
• W2584184235 hasConcept C4937899 @default.
• W2584184235 hasConcept C501593827 @default.
• W2584184235 hasConcept C523546767 @default.
• W2584184235 hasConcept C54355233 @default.
• W2584184235 hasConcept C547475151 @default.
• W2584184235 hasConcept C55493867 @default.
• W2584184235 hasConcept C86803240 @default.
• W2584184235 hasConcept C89423630 @default.
• W2584184235 hasConcept C94665300 @default.
• W2584184235 hasConceptScore W2584184235C104317684 @default.
• W2584184235 hasConceptScore W2584184235C176947019 @default.
• W2584184235 hasConceptScore W2584184235C2775945818 @default.
• W2584184235 hasConceptScore W2584184235C2776315533 @default.
• W2584184235 hasConceptScore W2584184235C2776352461 @default.
• W2584184235 hasConceptScore W2584184235C2777050379 @default.
• W2584184235 hasConceptScore W2584184235C2777058267 @default.
• W2584184235 hasConceptScore W2584184235C2777637488 @default.
• W2584184235 hasConceptScore W2584184235C2778523567 @default.
• W2584184235 hasConceptScore W2584184235C2778910516 @default.
• W2584184235 hasConceptScore W2584184235C2778983983 @default.
• W2584184235 hasConceptScore W2584184235C2779631663 @default.
• W2584184235 hasConceptScore W2584184235C2780493024 @default.
• W2584184235 hasConceptScore W2584184235C4937899 @default.
• W2584184235 hasConceptScore W2584184235C501593827 @default.
• W2584184235 hasConceptScore W2584184235C523546767 @default.
• W2584184235 hasConceptScore W2584184235C54355233 @default.
• W2584184235 hasConceptScore W2584184235C547475151 @default.
• W2584184235 hasConceptScore W2584184235C55493867 @default.
• W2584184235 hasConceptScore W2584184235C86803240 @default.
• W2584184235 hasConceptScore W2584184235C89423630 @default.
• W2584184235 hasConceptScore W2584184235C94665300 @default.
• W2584184235 hasIssue "5" @default.
• W2584184235 hasLocation W25841842351 @default.
• W2584184235 hasLocation W25841842352 @default.
• W2584184235 hasLocation W25841842353 @default.
• W2584184235 hasOpenAccess W2584184235 @default.
• W2584184235 hasPrimaryLocation W25841842351 @default.
• W2584184235 hasRelatedWork W1999604324 @default.
• W2584184235 hasRelatedWork W2096124422 @default.

• next